|
1
|
DeGroot LJ, Kaplan EL, McCormick M and
Straus FH: Natural history, treatment, and course of papillary
thyroid carcinoma. J Clin Endocrinol Metab. 71:414–424. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American Thyroid Association
Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid
Cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Durante C, Haddy N, Baudin E, Leboulleux
S, Harti D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De
Vathaire F and Schlumberger M: Long-term outcome of 444 patients
with distant metastases from papillary and follicular thyroid
carcinoma: Benefits and limits of radioiodine therapy. J Clin
Endocrinol Metab. 91:2892–2899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smit JW, Vielvoye GJ and Goslings BM:
Embolization for vertebral metastases of follicular thyroid
carcinoma. J Clin Endocrinol Metab. 85:989–994. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brose MS, Nutting CM, Jarzab B, Elisei R,
Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R,
Shong YK, et al: Sorafenib in radioactive iodine-refractory,
locally advanced or metastatic differentiated thyroid cancer: A
randomised, double-blind, phase 3 trial. Lancet. 384:319–328. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schulmberger M, Tahara M, Wirth LJ,
Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff
AO, et al: Lenvatinib versus placebo in radioiodine-refractory
thyroid cancer. N Engl J Med. 372:621–630. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang S, Pashtan I, Tsutsumi S, Xu W and
Neckers L: Cancer cells harboring MET gene amplification activate
alternative signaling pathways to escape MET inhibition but remain
sensitive to Hsp90 inhibitors. Cell Cycle. 8:2050–2056. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ruan M, Shen Y, Chen L and Li M: RECIST
1.1 and serum thyroglobulin measurements in the evaluation of
responses to sorafenib in patients with radioactive
iodine-refractory differentiated thyroid carcinoma. Oncol Lett.
6:480–486. 2013.PubMed/NCBI
|
|
9
|
Eilert KD and Foran DR: Polymerase
resistance to polymerase chain reaction inhibitors in bone. J
Forensic Sci. 54:1001–1007. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Basolo F, Pisaturo E, Pollina LE,
Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P and Pacini
F: N-ras mutation in poorly differentiated thyroid carcinomas:
Correlation with bone metastases and inverse correlation to
thyroglobulin expression. Thyroid. 10:19–23. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Melo M, da Rocha AG, Vinagre J, Batista R,
Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, et
al: TERT promoter mutations are a major indicator of poor outcome
in differentiated thyroid carcinoma. J Clin Endocrinol Metab.
99:E754–E765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Landa I, Ganly I, Chan TA, Mitsutake N,
Matsuse M, Ibrahimpasic T, Ghossein RA and Fagin JA: Frequent
somatic TERT promoter mutations in thyroid cancer: Higher
prevalence in advanced forms of the disease. J Clin Endocrinol
Metab. 9:E1562–E1566. 2013. View Article : Google Scholar
|
|
13
|
Dobashi Y, Sugimura H, Sakamoto A, Mernyei
M, Mori M, Oyama T and Machinami R: Stepwise participation of p53
gene mutation during dedifferentiation of human thyroid carcinomas.
Diagn Mol Pathol. 3:9–14. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wolter P, Beuselinck B, Pans S and
Schöffski P: Flare-up: An often un reported phenomenon nevertheless
familiar to oncologists prescribing tyrosine kinase inhibitors.
Acta Oncol. 48:621–624. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Desar IM, Mulder SF, Stillebroer AB, van
Spronsen DJ, van der Graaf WT, Mulders PF and van Herpen CM: The
reverse side of the victory: Flare up of symptoms after
discontinuation of sunitinib or sorafenib in renal cell cancer
patients. A report of three cases. Acta Oncol. 48:927–931. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yun KJ, Kim W, Kim EH, Kim MH, Lim DJ,
Kang MI and Cha BY: Accelerated disease progression after
discontinuation of sorafenib in a patient with metastatic papillary
thyroid cancer. Endocrinol Metab (Seoul). 29:388–393. 2014.
View Article : Google Scholar : PubMed/NCBI
|
